EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis

(2021) Andrea Dennis et al.   Frontiers in Endocrinology

FXR agonists for NASH: How are they different and what difference do they make?

(2021) Claus Kremoser   JOURNAL OF HEPATOLOGY

NAFLD 2020: The State of the Disease

(2020) Thomas G. Cotter et al.   GASTROENTEROLOGY

Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis

(2020) Rohit Loomba et al.   HEPATOLOGY

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

(2020) Ping An et al.   LIVER INTERNATIONAL

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

(2020) Stephen A. Harrison et al.   GASTROENTEROLOGY

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction

(2019) Shen Li et al.   FASEB JOURNAL

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

(2019) Paul J. Pockros et al.   LIVER INTERNATIONAL

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

(2019) Fernando Bril et al.   JOURNAL OF HEPATOLOGY

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Stephen A Harrison et al.   LANCET

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

(2019) Marcos Pedrosa et al.   Contemporary Clinical Trials

Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis

(2019) Mohammad Shadab Siddiqui et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects

(2018) A. Ahmad et al.   JOURNAL OF HEPATOLOGY

A critical review of endpoints for non-cirrhotic NASH therapeutic trials

(2018) Vlad Ratziu   JOURNAL OF HEPATOLOGY

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis

(2018) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

(2018) Saumya Jayakumar et al.   JOURNAL OF HEPATOLOGY

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study

(2016) Shozab S. Ali et al.   Nutrition & Metabolism

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

(2016) Len Verbeke et al.   Scientific Reports

Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Endogenous production of reactive oxygen species by the NADPH oxidase complexes is a determinant of γ-glutamyltransferase expression

(2011) Chandra Ravuri et al.   FREE RADICAL RESEARCH

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population

(2008) Constance E. Ruhl et al.   GASTROENTEROLOGY

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

(2008) Yan-Dong Wang et al.   HEPATOLOGY

Targeting bile-acid signalling for metabolic diseases

(2008) Charles Thomas et al.   NATURE REVIEWS DRUG DISCOVERY